STAAR Surgical (NASDAQ:STAA) Receives $43.33 Average PT from Brokerages

Shares of STAAR Surgical (NASDAQ:STAA - Get Free Report) have earned a consensus rating of "Hold" from the eight research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $43.33.

A number of research firms have recently issued reports on STAA. Stifel Nicolaus cut their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a "buy" rating on the stock in a report on Monday, August 26th. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a report on Thursday, October 31st. Finally, Canaccord Genuity Group cut their price target on shares of STAAR Surgical from $41.00 to $31.00 and set a "hold" rating on the stock in a report on Friday, November 1st.

STAAR Surgical Price Performance

STAA stock opened at $26.66 on Friday. STAAR Surgical has a 52-week low of $26.62 and a 52-week high of $52.68. The company's 50 day simple moving average is $31.29 and its 200-day simple moving average is $37.28. The firm has a market capitalization of $1.31 billion, a P/E ratio of 60.59 and a beta of 0.61.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Van ECK Associates Corp increased its stake in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock valued at $129,000 after buying an additional 393 shares during the period. Sei Investments Co. grew its position in STAAR Surgical by 2.7% in the second quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier's stock worth $718,000 after acquiring an additional 394 shares in the last quarter. Creative Planning grew its position in STAAR Surgical by 8.0% in the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier's stock worth $205,000 after acquiring an additional 408 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in STAAR Surgical by 3.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier's stock worth $540,000 after acquiring an additional 418 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC grew its position in STAAR Surgical by 2.3% in the second quarter. Linden Thomas Advisory Services LLC now owns 20,721 shares of the medical instruments supplier's stock worth $987,000 after acquiring an additional 469 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company's stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.